Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

被引:30
作者
Pro, Barbara
Advani, Ranjana H.
Brice, Pauline
Bartlett, Nancy L.
Rosenblatt, Joseph D.
Illidge, Tim
Matous, Jeffrey
Ramchandren, Radhakrishnan
Fanale, Michelle A.
Connors, Joseph M.
Yang, Yin
Huebner, Dirk
Kennedy, Dana A.
Shustov, Andrei R.
机构
关键词
D O I
10.1182/blood.V122.21.1809.1809
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1809
引用
收藏
页数:2
相关论文
empty
未找到相关数据